216 related articles for article (PubMed ID: 2161846)
41. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
42. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
43. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
[TBL] [Abstract][Full Text] [Related]
44. Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line.
Takahashi K; Kwaan HC; Koh E; Tanabe M
Biochem Biophys Res Commun; 1992 Feb; 182(3):1473-81. PubMed ID: 1540190
[TBL] [Abstract][Full Text] [Related]
45. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
47. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
Waltz DA; Sailor LZ; Chapman HA
J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190
[TBL] [Abstract][Full Text] [Related]
48. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
Conese M; Nykjaer A; Petersen CM; Cremona O; Pardi R; Andreasen PA; Gliemann J; Christensen EI; Blasi F
J Cell Biol; 1995 Dec; 131(6 Pt 1):1609-22. PubMed ID: 8522616
[TBL] [Abstract][Full Text] [Related]
49. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
50. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
51. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
52. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
Lund LR; Eriksen J; Ralfkiaer E; Rømer J
J Invest Dermatol; 1996 Apr; 106(4):622-30. PubMed ID: 8617995
[TBL] [Abstract][Full Text] [Related]
54. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
Ellis V; Danø K
Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
[TBL] [Abstract][Full Text] [Related]
55. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
[TBL] [Abstract][Full Text] [Related]
56. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
57. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
58. Characterization of urokinase receptor expression by human placental trophoblasts.
Zini JM; Murray SC; Graham CH; Lala PK; Karikó K; Barnathan ES; Mazar A; Henkin J; Cines DB; McCrae KR
Blood; 1992 Jun; 79(11):2917-29. PubMed ID: 1316787
[TBL] [Abstract][Full Text] [Related]
59. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
60. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Bruckner A; Filderman AE; Kirchheimer JC; Binder BR; Remold HG
Cancer Res; 1992 Jun; 52(11):3043-7. PubMed ID: 1375533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
